Switching From Semaglutide to Tirzepatide: What Actually Happens

You can switch from semaglutide to tirzepatide, but your dose doesn't carry over and there's no conversion table. You restart tirzepatide at 2.5 mg once a week for four weeks, then step up by 2.5 mg no sooner than every four weeks³. Good reasons to switch include a real stall at a maintenance dose, side effects or cost.

Yes, people switch, and it is a normal clinical conversation rather than an exotic one. What surprises most people is what does *not* come with them: the dose. Here is what actually happens, what the head-to-head data says, and the part nobody wants to hear about starting over.

Your dose does not carry across, and there is no conversion table

This is the single most important thing on this page. Semaglutide and tirzepatide are different molecules — tirzepatide acts at both the GIP and GLP-1 receptors, semaglutide only at GLP-1 — and they are not equipotent milligram for milligram. There is no published equivalence table, and any chart claiming to map "2.4 mg semaglutide = X mg tirzepatide" is somebody's guess dressed up as arithmetic.

What that means practically is that a switch is a restart. Tirzepatide's own label begins at 2.5 mg once weekly for four weeks — explicitly a starting dose intended to build tolerance rather than to treat — then steps up in 2.5 mg increments no sooner than every four weeks³. Being at the top of the semaglutide ladder does not let you skip that. Our tirzepatide dosage chart walks the whole ladder, and the dosing and titration guide covers both drugs.

What the head-to-head trial actually found

For a long time the comparison was indirect — separate trials, different populations, and a lot of confident internet arithmetic. That changed with a direct comparison: SURMOUNT-5 compared tirzepatide with semaglutide for the treatment of obesity, published in the New England Journal of Medicine in 2025¹. Earlier, SURPASS-2 had compared the two in type 2 diabetes².

Read those as evidence about *averages in a trial population*, not about you. A molecule that outperforms on average still has individual non-responders, and the person for whom semaglutide is working well and tolerably has a real reason to stay. We set the two side by side in semaglutide vs tirzepatide.

Reasons to switch that hold up

Response has genuinely stalled at a maintenance dose. Not week four, and not one flat week — a real trend at a real dose. Check how long semaglutide takes to work and the plateau page before concluding this, because most "it stopped working" turns out to be one of those two.

Side effects you cannot tolerate. Both drugs share the same gastrointestinal profile, so this is not guaranteed to improve — but individual tolerance does vary, and it is a legitimate thing to try under supervision. See side effects and how to manage them.

Supply or cost. A blunt but real reason. What each costs varies a lot by program and by whether you are on a compounded or branded route — tirzepatide cost without insurance and semaglutide cost without insurance have the current picture.

Reasons that do not hold up

"Tirzepatide is stronger so I will lose faster." You will spend the first sixteen weeks climbing a ladder from 2.5 mg, and it is entirely normal for loss to slow or stall during that window. A switch chasing speed often costs speed first.

A number from someone else's chart. See above. There is no conversion.

Because the first month was disappointing. That is a timeline problem, not a molecule problem.

The practical questions to ask before you move

Ask your prescriber four things, and ask them before you cancel anything.

*Where do I start, and how fast do I climb?* You will be starting at the bottom of the tirzepatide ladder.

*What is the gap between the last dose of one and the first of the other?* Semaglutide has an elimination half-life of about a week, so it does not vanish on the day you stop.

*What happens to my cost?* Program pricing for the two molecules is often different, and a switch can quietly move you into a different plan or a different tier.

*And can this program even prescribe both?* Not all can. A provider carrying only one molecule means a switch means a new provider, new intake and possibly a new price — which is exactly what our GLP-1 program board filters for, since it only ranks programs that publish a price for both.

The honest takeaway: switching is normal and often reasonable, but it is a restart, not a transfer. The dose does not carry, there is no conversion table worth trusting, and the first four months on the new molecule are a ladder. Switch for a real reason — a genuine stall at a real dose, intolerable side effects, or cost — and not because a comparison chart made the other drug sound faster.